While the clinical hold has been lifted on the MAGNITUDE-2 trial, it remains in place on the MAGNITUDE study.
The "Orphan Drugs Service Market Report 2025" has been added to ResearchAndMarkets.com's offering. The global orphan drugs ...
DelveInsight's DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
Investor's Business Daily on MSN
The 'confusing and unexpected' update that slammed Regenxbio stock
The FDA, on Wednesday, unexpectedly placed two of Regenxbio's experimental gene therapies on hold after a patient developed a ...
Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...
Life with Duchenne MD rarely follows a neat arc, writes columnist. That forces people to revisit the script and constantly ...
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
The Sahara Scheme was launched by the previous BJP government for the chronically ill patients from economically weaker ...
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...
A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...
The DUB inhibitors market is poised for steady growth, driven by rising interest in targeted protein degradation and novel oncology therapeutics. The growing prevalence of cancer and neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results